Savara (NASDAQ:SVRA) Stock Rating Upgraded by Wall Street Zen

Savara (NASDAQ:SVRA) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Savara Stock Performance

Shares of NASDAQ SVRA opened at $5.00 on Friday. The business’s 50 day moving average is $5.44 and its two-hundred day moving average is $5.43. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. Savara has a 1-year low of $3.34 and a 1-year high of $7.01. The stock has a market capitalization of $1.03 billion, a P/E ratio of -8.62 and a beta of 0.25.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). As a group, research analysts expect that Savara will post -0.61 EPS for the current year.

Hedge Funds Weigh In On Savara

Hedge funds have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC bought a new position in Savara during the 2nd quarter valued at about $69,000. WINTON GROUP Ltd bought a new stake in Savara in the second quarter worth about $151,000. Arizona State Retirement System lifted its stake in Savara by 34.0% in the second quarter. Arizona State Retirement System now owns 25,445 shares of the company’s stock worth $157,000 after purchasing an additional 6,456 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Savara during the second quarter valued at approximately $194,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Savara by 120.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 116,222 shares of the company’s stock valued at $716,000 after buying an additional 63,504 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara’s lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs.